BerGenBio

BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast

Bergen, Norway, 10 November 2017 - BerGenBio ASA, a clinical-stage

biopharmaceutical company developing novel, selective Axl kinase inhibitors for

multiple cancer indications, will announce its results for the third quarter

2017 on Friday, 17 November 2017.

A presentation by BerGenBio's senior management team will take place at 9.00 am

CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Bjørvika

The presentation will webcast live and the link will be available at

www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A

recording will be available shortly after the webcast has finished.

The results report and the presentation will be available at www.bergenbio.com

in the section: Investors/Reports and presentations from 7:00 am CET the same

day.

-Ends-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Tom Henrik Sundby

Finance Director, BerGenBio ASA

+47 477 54 415

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal